Search Bar & Filters
Found 21 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying HMB-002 in people with Von Willebrand Disease VWD to evaluate its safety, tolerability, how the body processes the drug, its effects, and preliminary efficacy. This first-in-human Phase 12 trial includes three parts to explore different dosing schedules and combinations with standard factor concentrates for various VWD types. The study aims to understand how HMB-002 works alone and alongside standard treatments in participants aged 16 to under 70 years. The study is divided into three parts Part A tests single ascending doses of HMB-002 administered under close monitoring to assess safety and drug behavior over about 12 weeks. Part B evaluates repeated doses over approximately 21 weeks to assess safety and initial effects on bleeding events. Part C studies a single dose of HMB-002 given with a regular factor concentrate dose in participants who already receive this treatment, lasting about 17 weeks. Dosing schedules in Part B depend on Part A results. Participants will be monitored closely throughout the study with safety assessments, blood tests, and evaluations of bleeding rates and factor activity from Day 1 up to Day 113. Researchers will track any treatment-emergent adverse events and measure pharmacokinetic parameters like maximum drug concentration and elimination half-life. They will also assess pharmacodynamic markers such as von Willebrand factor antigen and activity, and factor VIII activity. Overall participation lasts up to about 17 to 21 weeks depending on the study part.
Actively Recruiting
Researchers are evaluating treatments for patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated breast cancer that is locally advanced or metastatic. This phase III, global, randomized, open-label study compares the effectiveness and safety of inavolisib combined with fulvestrant versus alpelisib combined with fulvestrant. Participants have experienced disease progression during or after therapy with cyclin dependent kinase 46 inhibitors combined with endocrine therapy. Participants receive study drugs in repeated 28-day cycles. Inavolisib is taken orally once daily at 9 mg on days 1 to 28 of each cycle, while fulvestrant is administered at 500 mg on days 1 and 15 of the first cycle and day 1 of subsequent cycles. The comparator group receives alpelisib at 300 mg orally once daily plus fulvestrant on the same schedule. A substudy evaluates the effect of inavolisib plus fulvestrant on the metabolism of certain enzyme substrates by administering midazolam, omeprazole, and bupropion on specified days within the first cycle. Participants undergo regular assessments including tumor evaluations per RECIST criteria, blood tests, and monitoring of drug levels. The primary outcome measures progression-free survival assessed by independent review up to approximately 64 months. Secondary outcomes include overall survival, response rates, quality of life, and safety events monitored up to about 85 months. The study includes frequent visits during treatment cycles and follow-ups to evaluate side effects and long-term outcomes.
Actively Recruiting
Researchers are investigating why some breast cancers resist anti-cancer treatments by studying tumor tissue and blood samples from participants with HER2 positive, hormone receptor positive, or triple negative breast cancer. This research focuses on understanding mechanisms of resistance in patients who have either newly appearing or progressing metastatic lesions while undergoing therapy. The study is designed as a Phase 4 interventional trial with multiple participant groups based on disease progression and resistance patterns. Participants are assigned to different groups depending on whether they have newly appearing or recurrent metastatic lesions while on treatment, or if their tumor lesions are progressing during therapy. The study involves collecting tumor tissue and blood samples at the time of disease progression or recurrence to measure changes in HER2 protein and gene levels, estrogen receptor protein levels, genes related to resistance, and immune markers. These procedures help researchers understand resistance mechanisms related to various breast cancer therapies. During the study, participants will have blood drawn on the same day a tumor tissue sample is taken from a progressive lesion. Researchers will monitor changes over periods of at least six months or less, depending on the cohort. Assessments include molecular and immune profiling to track resistance development. Participants are expected to be involved in procedures to obtain tissue and blood samples, with safety and progression carefully monitored throughout the trial, which is planned to continue until early 2028.
Actively Recruiting
Researchers are evaluating the medicine BI 3000202 in adults with moderate to severe systemic lupus erythematosus SLE to find out if it helps manage the condition. This phase II study randomly assigns participants to one of five groups, including four different doses of BI 3000202 and one placebo group. The goal is to determine the best dose while monitoring the safety and effects of the medicine. Participants take their assigned tablets daily for one year while continuing their regular SLE treatments. The study involves a randomized, placebo-controlled, double-blind design with parallel groups. Four groups receive varying doses of BI 3000202, and one group receives placebo tablets that look the same but contain no medicine. During the study, participants visit the study site regularly for health checks, monitoring of any side effects, and assessments of their disease activity using tools like the Systemic Lupus Erythematosus Responder Index. The study lasts a bit longer than one year, allowing thorough evaluation of treatment effects and safety. Researchers compare results among the groups to understand the medicines impact on SLE.
Actively Recruiting
This trial investigates treatment options for adults aged 16 to 69 with early-stage classical Hodgkin lymphoma, specifically stage I or II supradiaphragmatic disease without mediastinal bulk or B symptoms. The study compares two chemotherapy regimens ABVD and A2VD, using a PET response-adapted design to adjust therapy based on treatment response. It is a phase III, randomized, open-label trial conducted internationally and sponsored by University College London and Canadian Cancer Trials Group. Participants will be randomly assigned to receive either ABVD chemotherapy doxorubicin, bleomycin, vinblastine, and dacarbazine or A2VD chemotherapy doxorubicin, brentuximab vedotin, vinblastine, and dacarbazine with growth factor support. After two 28-day cycles, a PET-CT scan will assess response using the Deauville score to guide further treatment. Patients with scores 1-3 receive one more cycle those with score 4 receive two more cycles followed by involved site radiotherapy patients with score 5 discontinue trial treatment and receive alternative therapy as determined by their clinician. Throughout the study, participants undergo PET-CT scans and clinical assessments to monitor treatment response and safety. They will be followed for at least five years post-treatment to evaluate progression-free survival and other outcomes such as event-free survival, overall survival, and incidence of second cancers or cardiovascular disease. Safety and toxicity are monitored from treatment start until 30 days after completion. The overall study period extends until 2032.
Actively Recruiting
Researchers are conducting a multi-centre observational study to better understand giant cell arteritis GCA and polymyalgia rheumatica PMR, conditions mainly affecting people over 50 years old. The study aims to identify genetic factors that influence susceptibility to these diseases to provide new insights into how they develop. It includes both retrospective participants with confirmed diagnoses and prospective participants suspected of having these conditions, with some patients also enrolled in a registry monitoring tocilizumab treatment for relapsing or refractory GCA. The study collects detailed clinical, imaging, and molecular data, including genetic and proteomic analyses, from participants to characterize disease subtypes and impacts. Researchers also assess quality of life through patient-reported outcomes and track long-term prognosis by linking to health records. The study explores environmental factors and co-existing conditions to improve diagnosis, prognosis, and monitoring of disease activity, especially for patients receiving synthetic or biological disease-modifying anti-rheumatic drugs. Participants provide information during baseline assessments, including blood and urine samples for analysis, and complete questionnaires about their symptoms and quality of life. Follow-up occurs through health record review over an average of one year to evaluate diagnosis and disease outcomes. The primary measure is genetic susceptibility, with secondary outcomes focusing on disease characteristics, life impact, diagnosis, and disease activity. The study is sponsored by the University of Leeds and started in 2005, continuing through 2028.
Actively Recruiting
Bowel cancer is a common and serious cancer, ranking fourth in occurrence and second in cause of cancer deaths in the UK. Despite treatment advances, over 40% of patients die within five years, mostly due to the cancer spreading to other organs, called metastases. Current research focuses on additional treatments before or after surgery, but identifying which patients benefit from these treatments is challenging. This study investigates whether cancer spreads through blood vessels rather than lymph nodes, aiming to improve patient treatment selection. This research is a retrospective, non-interventional study analyzing archival tissue samples collected during routine care. The study examines genetic material from primary tumors, areas of blood vessel invasion called Extramural Venous Invasion EMVI, tumor deposits, lymph nodes, and distant metastases. By reconstructing the tumors family tree, researchers aim to map how the cancer spreads and test if the vascular route is more important than lymph nodes in metastasis. Participants have already provided tissue samples through their medical care, so no new treatments or interventions occur. Researchers will compare genetic and staining profiles of tumor samples and evaluate survival based on tumor origins. The main measure is the link between EMVI, tumor deposits, lymph nodes, and distant metastases, with results expected one year after the last patient is registered. This study is observational and does not involve treatment changes or additional visits.
Actively Recruiting
Researchers are evaluating the use of two types of MRI scans and two biopsy methods to improve prostate cancer diagnosis. The study focuses on whether biparametric MRI bpMRI, which is shorter and does not use contrast dye, can be an alternative to the longer multiparametric MRI mpMRI that uses gadolinium contrast. It also compares image-fusion targeted biopsy, which overlays MRI and ultrasound images during biopsy, with visual-registration targeted biopsy, where biopsy locations are chosen by looking at MRI images separately. Participants first receive either the mpMRI or bpMRI scan. If the MRI suggests cancer, the clinical team decides if a biopsy is needed. Those advised for biopsy undergo either a visual-registration targeted biopsy or an image-fusion targeted biopsy. Both biopsy methods include taking systematic tissue samples to check for cancer. The study does not blind participants or doctors to the MRI or biopsy type used. During the study, participants undergo MRI scans and possibly biopsies based on clinical advice. Researchers collect data on how many clinically significant prostate cancers are detected within 12 weeks of enrollment. They also assess any adverse events related to MRI and biopsy procedures, patient-reported outcomes, and accuracy of cancer detection using different scoring systems. The total duration for outcome assessment is up to 12 weeks after joining the study.
Actively Recruiting
Researchers are studying the use of magnetic resonance tumour regression grade mrTRG as a new imaging biomarker to guide treatment decisions for patients with locally advanced rectal cancer. This phase III trial is unique in the UK as it offers a watch and wait approach for patients showing a good response to preoperative treatment, potentially avoiding surgery. The trial aims to validate mrTRGs ability to identify patients who can safely defer surgery and those who may need intensified treatment, thus tailoring care based on MRI findings. Participants are randomly assigned to one of two groups. The control group receives management according to national guidelines with post-treatment MRI scans interpreted without mrTRG assessment. The intervention group has their post-treatment MRI scans evaluated by specially trained radiologists to assign an mrTRG grade. Patients with a good response mrTRG 1 & 2 are offered a watch and wait approach to avoid surgery, while those with a poor response mrTRG 3-5 have their cases reviewed by a local colorectal multidisciplinary team for further treatment planning and surveillance. Treatment decisions, including chemotherapy use, follow routine clinical practice and are documented but not dictated by the trial. Participants undergo regular monitoring for up to five years, including routine post-treatment MRI scans following the MERCURY protocol and quality of life questionnaires at registration, 3 years, and 5 years. The study assesses if surgery can be safely avoided after a good MRI response and tracks surgical outcomes, survival, quality of life, and economic impact. Additional evaluations include reproducibility of mrTRG readings, molecular and immunological markers, and circulating tumor DNA to predict relapse. This long-term follow-up aims to improve personalized treatment for rectal cancer patients.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of CSL511 fibrinogen concentrate compared to cryoprecipitate in adults with pseudomyxoma peritonei PMP undergoing cytoreductive surgery CRS combined with hyperthermic intraperitoneal chemotherapy HIPEC. This phase 3, randomized, open-label, controlled trial focuses on patients expected to have significant blood loss during surgery, aiming to improve hemostatic outcomes. Participants are randomly assigned to receive either the CSL511 fibrinogen concentrate or cryoprecipitate through intravenous infusion during surgery. The study assesses treatments during surgery and up to 24 hours afterward, focusing on blood clotting success. Secondary measures include adverse events monitoring for up to 30 days, blood loss, blood product requirements, surgery duration, and recovery parameters. Throughout the trial, participants undergo evaluations during surgery and postoperatively, including blood tests to monitor coagulation and fibrinogen levels up to 8 days after surgery. Researchers track the number of doses administered, blood loss, length of hospital and intensive care stays, reoperations, and mortality within 30 days. The primary outcome is the percentage of participants achieving overall hemostatic success from surgery through 24 hours post-surgery.
1-10 of 21
1